We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $999B
1-Year Est. Return 46.22%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+4.72%
1 Year Est. Return
+46.22%
3 Year Est. Return
+150.45%
5 Year Est. Return
+185.95%
10 Year Est. Return
+871.56%
AUM
$867B
AUM Growth
-$1.1B
Cap. Flow
-$19.5B
Cap. Flow %
-2.25%
Top 10 Hldgs %
35.42%
Holding
3,110
New
92
Increased
1,805
Reduced
946
Closed
96

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$2.81B
2
BA icon
Boeing
BA
+$1.68B
3
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.33B
4
APH icon
Amphenol
APH
+$1.11B
5
CME icon
CME Group
CME
+$902M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$3.65B
2
AMD icon
Advanced Micro Devices
AMD
+$2.51B
3
UNH icon
UnitedHealth
UNH
+$2.06B
4
UBER icon
Uber
UBER
+$1.84B
5
ADBE icon
Adobe
ADBE
+$1.44B

Sector Composition

Rank Sector Weight
1 Technology 33.21%
2 Healthcare 12.77%
3 Consumer Discretionary 11.71%
4 Financials 11.15%
5 Communication Services 9.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MGX icon
2951
Metagenomi Therapeutics
MGX
$43.4M
$39K ﹤0.01%
+10,755
New +$25.9K
LNAI
2952
Lunai Bioworks
LNAI
$8.75M
$38K ﹤0.01%
565
+366
+184% +$24.3K
POWW icon
2953
Outdoor Holding Co
POWW
$266M
$37K ﹤0.01%
33,044
– –
WVVI icon
2954
Willamette Valley Vineyards
WVVI
$9.66M
$37K ﹤0.01%
10,850
– –
PAYS icon
2955
Paysign
PAYS
$715M
$34K ﹤0.01%
11,100
– –
DARE icon
2956
Dare Bioscience
DARE
$15.3M
$33K ﹤0.01%
10,491
– –
OPAD icon
2957
Offerpad Solutions Inc. Class A Common Stock
OPAD
$16.2M
$32K ﹤0.01%
1,093
– –
RDZN icon
2958
Roadzen
RDZN
$119M
$32K ﹤0.01%
+14,460
New +$17.9K
WWR icon
2959
Westwater Resources
WWR
$67.5M
$32K ﹤0.01%
45,000
– –
ENZ
2960
DELISTED
Enzo Biochem, Inc.
ENZ
$32K ﹤0.01%
44,800
– –
AKYA
2961
DELISTED
Akoya BioSciences
AKYA
$31K ﹤0.01%
+13,116
New +$34.7K
BDTX icon
2962
Black Diamond Therapeutics
BDTX
$108M
$31K ﹤0.01%
14,182
-365,762
-96% -$1.05M
STIM icon
2963
Neuronetics
STIM
$209M
$31K ﹤0.01%
19,100
– –
APLT
2964
DELISTED
Applied Therapeutics
APLT
$30K ﹤0.01%
34,763
-986,108
-97% -$6.18M
IQ icon
2965
iQIYI
IQ
$984M
$30K ﹤0.01%
14,900
– –
BRN icon
2966
Barnwell Industries
BRN
$13.6M
$28K ﹤0.01%
18,200
– –
COOK icon
2967
Traeger
COOK
$130M
$28K ﹤0.01%
229
– –
NAUT icon
2968
Nautilus Biotechnolgy
NAUT
$123M
$28K ﹤0.01%
16,078
– –
HBIO icon
2969
Harvard Bioscience
HBIO
$36.2M
$27K ﹤0.01%
1,262
– –
LIDR icon
2970
AEye
LIDR
$56.5M
$26K ﹤0.01%
20,196
– –
PYXS icon
2971
Pyxis Oncology
PYXS
$239M
$25K ﹤0.01%
15,720
– –
ABOS icon
2972
Acumen Pharmaceuticals
ABOS
$162M
$24K ﹤0.01%
13,616
-836,003
-98% -$2.01M
ANGI icon
2973
Angi Inc
ANGI
$220M
$24K ﹤0.01%
1,410
-1,990
-59% -$42.4K
GUTS icon
2974
Fractyl Health
GUTS
$77.3M
$24K ﹤0.01%
11,313
-68,500
-86% -$159K
MRNS
2975
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$24K ﹤0.01%
44,200
– –

Similar funds

T. Rowe Price Associates's Q4 2024 Portfolio in Review

As of Q4 2024, T. Rowe Price Associates held 3,110 positions worth $867B, down 0.13% from $869B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

T. Rowe Price Associates's Q4 2024 filing shows 92 new, 1,805 increased, 946 reduced and 96 closed positions. Its largest new stake was South Bow Corp: 12,337,055 shares worth $291M. The largest sale was Apple, an estimated $3.65B.

By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2024 buy was South Bow Corp: 12,337,055 shares worth $291M.
  • T. Rowe Price Associates added most to Broadcom in Q4 2024, an estimated $2.81B increase.
  • T. Rowe Price Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $3.65B.
  • T. Rowe Price Associates fully exited Tempus AI in Q4 2024, selling an estimated $292M.
  • T. Rowe Price Associates's ten largest holdings make up 35% of its $867B portfolio in Q4 2024.
  • T. Rowe Price Associates opened 92 new positions and closed 96 in Q4 2024.
  • T. Rowe Price Associates's portfolio value fell 0.13% quarter-over-quarter to $867B.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.